GlassScriptPhysician profile
Bradley Dwight Hardy
NPI 1912240052
$16,686.63
in general payments reported to CMS, 2019-2025
52 companies · $1,710 in 2025
The $1,710 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,021 · 2020: $2,167 · 2021: $3,204 · 2022: $2,767 · 2023: $2,589 · 2024: $2,229 · 2025: $1,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,528.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,027.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,652.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,563.70 | 2021-2025 | |
| Lilly USA, LLC | $1,560.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,557.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $997.35 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $982.30 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $826.29 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $822.94 | 2019-2024 | Jardiance, Ofev |
| Amgen INC. | $737.72 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $547.00 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $467.69 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.56 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $254.84 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $240.50 | 2023-2025 | Cologuard Collection Kit |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.